A Phase 2 interventional study of Standard chemotherapy and bevacizumab [Avastin] in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 28 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-02.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
How we know · 6 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies testing bevacizumab in Breast Neoplasms — 9 open to participants now, 10 under way, none of them phase 3. Bevacizumab · Breast Neoplasms.
Among the 131 studies testing bevacizumab in Breast Neoplasms, this one is the 69th largest by enrollment of the 130 interventional ones that give a count, is one of 24 that started in 2008, is one of 89 in phase 2, and was the 72nd registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →9 of the 131 studies testing bevacizumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18–70 · Women only
Yukinori Ozaki · Sites in Japan
Ages 18+
Tongji Hospital · Sites in China
Ages 18+
Lebanese University · Sites in Lebanon
Ages 18+
Henan Cancer Hospital · Sites in China
Ages 18–70 · Women only
By country, each count listing its studies:
Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 96 · Phase 3 19 · Phase 4 4
First in 2000; this study’s year is marked. 24 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 58 across the 130 interventional studies. Of the 106 that completed or were terminated, 59 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 131 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 88 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 27 under way, 13 of them phase 3. Of 194 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 132nd largest by enrollment of the 170 interventional ones that give a count, is one of 11 that started in 2008, is one of 65 in phase 2, and was the 38th registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
3 of the studies testing bevacizumab in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05398861Henan Cancer HospitalUtidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer | 2026-12-30 |
| NCT07359404YING FANSacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC | 2026-12-31 |
| NCT07150208Fudan UniversityT-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 131 studies testing bevacizumab in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This single arm study will assess the efficacy and safety of preoperative treatment with Avastin combined with Herceptin-based chemotherapy in patients with primary inflammatory HER2-positive breast cancer. Patients will be treated with a total of 8 cycles of pre-operative chemotherapy + Avastin + Herceptin. The anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Standard chemotherapy · Drug: bevacizumab [Avastin] · Drug: trastuzumab [Herceptin]
As prescribed
15mg/kg iv 3 weekly in cycles 1-8
8mg/kg iv loading dose followed by 6mg/kg iv 3 weekly in cycles 5-8.
Percentage of Participants With a Pathological Complete Response (PCR) According to the Sataloff Classification
PCR was assessed at the time of definitive surgery according to Sataloff classification and centrally reviewed by an independent committee under blinded conditions. Pathological response was defined based on the therapeutic response at the primary tumor site and axillary lymph nodes. Primary tumor response criteria were as follows: T-A (Total / near total therapeutic effect), T-B (Subjectively greater than \[\>\] 50 percent \[%\] therapeutic effect but less than \[\<\] T-A), T-C (\<50% therapeutic effect, but effect evident), T-D (No therapeutic effect). Axillary lymph node response: N-A (Evidence of therapeutic effect, no metastases), N-B (No therapeutic effect, no nodal metastases), N-C (Nodal metastasis but evident therapeutic effect), N-D (Nodal metastasis with no therapeutic effect). T-A and N-A or T-A and N-B responses were defined as PCR and all other tumor responses as non-responders. Participants with missing values were considered as non-responders.
Time frame: From baseline through Week 25 (Up to 6 months)
Percentage of Participants With a PCR According to the Chevallier Classification
PCR was assessed at the time of definitive surgery according to Chevallier classification and centrally reviewed by an independent committee under blinded conditions. The Chevallier classification for grading of therapeutic effect related to the primary tumor site and axillary lymph nodes was defined by microscopic changes as follows - Grade 1: Disappearance of all tumors either in the breast or in the nodes, Grade 2: Persistence of carcinoma in situ in the breast only and no nodal invasion, Grade 3: Presence of invasive carcinoma with stromal alteration, Grade 4: Presence of invasive carcinoma without modification. Grade 1 response was considered as PCR. Participants with missing values were considered as non-responders.
Time frame: From baseline through Week 25 (Up to 6 months)
Percentage of Participants Who Were Responders Based on Inflammatory Signs From Baseline at Cycle 5 and Final Treatment Visit
Breast tumor was physically evaluated during the study which included assessment for inflammatory signs and for overall clinical response. Participant with response from baseline based on inflammatory signs at Cycle 5 and final treatment visit were presented.
Time frame: Baseline, Cycle 5 (Week 15), Neo-adjuvant treatment final visit (Week 25)
Percentage of Participants Who Were Responders Based on Overall Clinical Response From Baseline at Cycle 5 and Final Treatment Visit
Breast tumor was physically evaluated during the study which included assessment for inflammatory signs and for overall clinical response. Participant with response from baseline based on overall clinical response at Cycle 5 and final treatment visit were presented.
Time frame: Baseline, Cycle 5 (Week 15), Neo-adjuvant treatment final visit (Week 25)
Number of Participants Who Underwent Mastectomy
Surgery included a mastectomy with axillary node dissection and had to be performed at least 4 weeks after the last infusion of neoadjuvant bevacizumab treatment.
Time frame: Anytime between Week 26 and Week 29
Percentage of Participants With Macroscopically Visible Tumor
Local pathologists assessed the tumor whether it was macroscopically visible or not and percentage of participants for whom the tumor was macroscopically visible was reported.
Time frame: Anytime between Week 26 and Week 29
Percentage of Participants Who Underwent Lymph Node Resection
Among the participants who were planned to undergo mastectomy, lymph node resection was also performed by the physician depending up on the participant's breast cancer grades.
Time frame: Anytime between Week 26 and Week 29
Breast Cancer Marker CA15.3 at Baseline, Neoadjuvant Final Visit and Change From Baseline at Neoadjuvant Final Visit
Time frame: Baseline, Neoadjuvant Final Visit (Week 25)
Percentage of Participants Who Were Disease Free at 3 and 5 Years
A participant was considered disease free if the participant did not experience any of the following events: local recurrence in the ipsilateral breast following lumpectomy, regional recurrence, distant recurrence, contralateral breast cancer, second primary cancer (other than squamous or basal cell carcinoma of the skin, melanoma in situ, carcinoma in situ of the cervix, colon carcinoma in situ, or lobular carcinoma in situ of the breast), or death from any cause.
Time frame: 3, 5 years
Disease Free Survival (DFS) Duration
DFS was estimated using Kaplan-Meier method.
Time frame: Up to 5 Years
Percentage of Participants Who Were Recurrence Free at 3 and 5 Years
A participant was considered recurrence free if the participant did not experience local or regional recurrence (wall or axillaries nodes), or occurrence of distant metastases (including soft tissue and distal lymph nodes).
Time frame: 3, 5 years
Recurrence Free Survival (RFS) Duration
RFS was estimated using Kaplan-Meier method.
Time frame: Up to 5 Years
Percentage of Participants Who Were Alive at 3 and 5 Years
Time frame: 3, 5 years
Overall Survival (OS) Duration
OS was defined as the time from the first administration of neoadjuvant treatment to death of any cause. OS was estimated using Kaplan-Meier method.
Time frame: Up to 5 years
| Milestone | Bevacizumab + Trastuzumab Chemotherapy |
|---|---|
| Started | 52 |
| Completed | 52 |
| Not completed | 0 |
PCR was assessed at the time of definitive surgery according to Sataloff classification and centrally reviewed by an independent committee under blinded conditions. Pathological response was defined based on the therapeutic response at the primary tumor site and axillary lymph nodes. Primary tumor response criteria were as follows: T-A (Total / near total therapeutic effect), T-B (Subjectively greater than \[\>\] 50 percent \[%\] therapeutic effect but less than \[\<\] T-A), T-C (\<50% therapeutic effect, but effect evident), T-D (No therapeutic effect). Axillary lymph node response: N-A (Evidence of therapeutic effect, no metastases), N-B (No therapeutic effect, no nodal metastases), N-C (Nodal metastasis but evident therapeutic effect), N-D (Nodal metastasis with no therapeutic effect). T-A and N-A or T-A and N-B responses were defined as PCR and all other tumor responses as non-responders. Participants with missing values were considered as non-responders.
| percentage of participants | Bevacizumab + Trastuzumab |
|---|---|
| Percentage of Participants With a Pathological Complete Response (PCR) According to the Sataloff Classification | 63.46 (49.41 to 77.51) |
PCR was assessed at the time of definitive surgery according to Chevallier classification and centrally reviewed by an independent committee under blinded conditions. The Chevallier classification for grading of therapeutic effect related to the primary tumor site and axillary lymph nodes was defined by microscopic changes as follows - Grade 1: Disappearance of all tumors either in the breast or in the nodes, Grade 2: Persistence of carcinoma in situ in the breast only and no nodal invasion, Grade 3: Presence of invasive carcinoma with stromal alteration, Grade 4: Presence of invasive carcinoma without modification. Grade 1 response was considered as PCR. Participants with missing values were considered as non-responders.
| percentage of participants | Bevacizumab + Trastuzumab |
|---|---|
| Percentage of Participants With a PCR According to the Chevallier Classification | 53.85 (39.34 to 68.36) |
Breast tumor was physically evaluated during the study which included assessment for inflammatory signs and for overall clinical response. Participant with response from baseline based on inflammatory signs at Cycle 5 and final treatment visit were presented.
| percentage of participants | Bevacizumab + Trastuzumab |
|---|---|
| Response from baseline at Week 15 (n=43) | 88.4 |
| Response from baseline at Week 25 (n=42) | 100.0 |
Breast tumor was physically evaluated during the study which included assessment for inflammatory signs and for overall clinical response. Participant with response from baseline based on overall clinical response at Cycle 5 and final treatment visit were presented.
| percentage of participants | Bevacizumab + Trastuzumab |
|---|---|
| Response from baseline at Week 15 (n=44) | 90.9 |
| Response from baseline at Week 25 (n=45) | 97.8 |
Surgery included a mastectomy with axillary node dissection and had to be performed at least 4 weeks after the last infusion of neoadjuvant bevacizumab treatment.
| participants | Bevacizumab + Trastuzumab |
|---|---|
| Number of Participants Who Underwent Mastectomy | 49 |
Local pathologists assessed the tumor whether it was macroscopically visible or not and percentage of participants for whom the tumor was macroscopically visible was reported.
| percentage of participants | Bevacizumab + Trastuzumab |
|---|---|
| Percentage of Participants With Macroscopically Visible Tumor | 26.5 |
Among the participants who were planned to undergo mastectomy, lymph node resection was also performed by the physician depending up on the participant's breast cancer grades.
| percentage of participants | Bevacizumab + Trastuzumab |
|---|---|
| Percentage of Participants Who Underwent Lymph Node Resection | 98.0 |
| Units per milliliter (U/mL) | Bevacizumab + Trastuzumab |
|---|---|
| Baseline (n=52) | 39.66 ± 79.49 |
| Neoadjuvant final visit (n=37) | 29.39 ± 10.06 |
| Change in CA15.3 at neoadjuvant final visit (n=37) | -3.39 ± 33.05 |
A participant was considered disease free if the participant did not experience any of the following events: local recurrence in the ipsilateral breast following lumpectomy, regional recurrence, distant recurrence, contralateral breast cancer, second primary cancer (other than squamous or basal cell carcinoma of the skin, melanoma in situ, carcinoma in situ of the cervix, colon carcinoma in situ, or lobular carcinoma in situ of the breast), or death from any cause.
| percentage of participants | Bevacizumab + Trastuzumab |
|---|---|
| 3 years | 66.7 (52.0 to 77.8) |
| 5 years | 60.8 (46.1 to 72.7) |
DFS was estimated using Kaplan-Meier method.
| months | Bevacizumab + Trastuzumab |
|---|---|
| Disease Free Survival (DFS) Duration | NA (NA to NA) |
A participant was considered recurrence free if the participant did not experience local or regional recurrence (wall or axillaries nodes), or occurrence of distant metastases (including soft tissue and distal lymph nodes).
| percentage of participants | Bevacizumab + Trastuzumab |
|---|---|
| 3 years | 69.7 (54.8 to 80.5) |
| 5 years | 65.4 (50.4 to 76.9) |
RFS was estimated using Kaplan-Meier method.
| months | Bevacizumab + Trastuzumab |
|---|---|
| Recurrence Free Survival (RFS) Duration | NA (NA to NA) |
| percentage of participants | Bevacizumab + Trastuzumab |
|---|---|
| Alive at 3 years | 90.0 (77.6 to 95.7) |
| Alive at 5 years | 81.8 (67.9 to 90.1) |
OS was defined as the time from the first administration of neoadjuvant treatment to death of any cause. OS was estimated using Kaplan-Meier method.
| months | Bevacizumab + Trastuzumab |
|---|---|
| Overall Survival (OS) Duration | NA (NA to NA) |
Collected over From Baseline until end of study (Up to approximately 6 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bevacizumab + Trastuzumab | — | 20/52 (38.5%) | 52/52 (100%) |
| Event | Bevacizumab + Trastuzumab |
|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 6/52 |
| LeukopeniaBlood and lymphatic system disorders | 6/52 |
| Febrile bone marrow aplasiaBlood and lymphatic system disorders | 5/52 |
| Impaired healingGeneral disorders | 3/52 |
| Anal abscessInfections and infestations | 2/52 |
| Ejection fraction decreasedInvestigations | 2/52 |
| VomitingGastrointestinal disorders | 1/52 |
| HyperthermiaGeneral disorders | 1/52 |
| MalaiseGeneral disorders | 1/52 |
| PyrexiaGeneral disorders | 1/52 |
| Event | Bevacizumab + Trastuzumab |
|---|---|
| AstheniaGeneral disorders | 41/52 |
| NauseaGastrointestinal disorders | 36/52 |
| AlopeciaSkin and subcutaneous tissue disorders | 36/52 |
| Mucosal inflammationGeneral disorders | 34/52 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 33/52 |
| ProteinuriaRenal and urinary disorders | 32/52 |
| NeutropeniaBlood and lymphatic system disorders | 24/52 |
| HypertensionVascular disorders | 21/52 |
| Radiation skin injuryInjury, poisoning and procedural complications | 19/52 |
| VomitingGastrointestinal disorders | 18/52 |
Intent to treat population (ITT): Included all enrolled participants who had at least 1 post baseline assessment.
| Age, Continuous(years) | Bevacizumab + Trastuzumab |
|---|---|
| Mean | 51.48 ± 9.78 |
| Sex: Female, Male(Participants) | Bevacizumab + Trastuzumab |
|---|---|
| Female | 52 |
| Male | 0 |
The record gives a start of Oct 2008, a primary completion of Apr 2010 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2016, 5 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bevacizumab · Trastuzumab